For the latest updates to Cannabics Pharmaceuticals, follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn and Instagram @Cannabics_Pharmaceuticals. First announced in a press release on June 29, 2018, and then on February 7, 2019, the two companies received an expertise that they believe identifies a possible pathway with the U.S. Food and Drug Administration for eye therapy with cannabinoids. In accordance with the joint enterprise agreement signed on 7 February 2019, the successful conclusion of the above agreement means the initial conclusion of the agreement and the start of the agreement, subject to the creation of the joint venture and the completion of a business plan acceptable to both parties. Wize`s strategy involves the involvement of local or multinational distributors to ensure the distribution of LO2A. The company has conducted a Phase 2 study with LO2A in patients with CCH and is currently conducting a Phase 4 study with LO2A for patients with Sjogren`s. Certain statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such statements include, but are not limited to, statements that are identified by words such as “believes,” “expected,” “expected,” “estimated,” “project,” “plan,” “goals,” “projects” and similar expressions. We use z.B forward-looking statements when we talk about the creation of the joint venture and the agreement and timing of a business plan. the belief that the expertise identifies a possible path with the FDA for eye therapy with cannabinoids, the intention of the parties to create a joint venture that wants to pursue cannabinoid-based compositions, which can benefit patients with eye diseases suffering from diseases and the belief that the introduction of cannabinoid-based therapies in modern medicine can be used as a treatment for a large number of diseases.
The statements contained in this press release are based on the current beliefs and expectations of the management of Wize Pharma and Cannabics and are subject to considerable risks and uncertainties. Actual results may differ from those presented in the forward-looking statements. Many factors can cause or contribute to these differences, including, but not limited to, the results of clinical trials and/or other studies; The challenges of new product development initiatives The effects of competitive products, the ability of the parties to concede and protect their intellectual property, the ability of the parties in the future to obtain additional capital necessary to maintain their respective activities, changes in government policy and/or regulation, potential litigation by or against one of the parties, any state review of the parties` products or practices and other risks that are discussed from time to time in each of Wi Pharmaze and Cannabics` submissions to the Securities And Supervisory Authority.